ReviewFrontiers in endocrinology2025
The extra-thyroidal distribution of sodium iodide symporter.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A nomogram predicting dysphagia risk after adjuvant iodine-131 therapy in patients with papillary thyroid carcinoma.Nuclear medicine communications · 2026Article
- Iodine and Its Impact on the Immune System of Humans and Domesticated Mammals: A Narrative Review.Nutrients · 2026Review
- An Approach Toward Radioiodination and Radiopharmacological Evaluation of a Carborane-Containing Analog of Indomethacin.Molecules (Basel, Switzerland) · 2026Article
- NIS-Centered Reporter Gene Imaging and Radionuclide-Integrated Nanoplatforms for Quantitative Tracking of Immune Cell Therapy in Oncology and Inflammatory Disease Models.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Iodine in Health and Disease: A Comprehensive Review.Nutrients · 2026Review
- Radioiodination of Two Carborane-Based Dual Cyclooxygenase-2/5-Lipoxygenase Inhibitors and Their In Vitro and In Vivo Evaluation.Chembiochem : a European journal of chemical biology · 2026Article
- Elevated NIS Expression Correlates with Chemoresistance in Triple-Negative Breast Cancer: Potential Link to FOXA1 Activity.Medical sciences (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The intrinsic transmembrane protein known as sodium iodide symporter (NIS) facilitates the active transport of iodide across the basolateral membrane of thyroid follicular cells. Iodine is an essential molecule that is used to produce the classical thyroid hormones that contribute to growth and development of various parts of the body and play a significant role as metabolic regulators. The cloning of the human NIS gene in 1996 has led to widespread advancements in thyroid-related research. Amongst these, the significant discovery of extra-thyroidal expression of thyroid-specific genes and proteins such as NIS in both human and non-human subjects has been well documented. The identification of NIS protein in non-thyroid tissue provides potential targets for therapeutic interventions aimed at modulating autoimmune responses in various parts of the body. In the diagnosis and prognosis of different types of cancer, the molecular and protein expression of NIS may prove to be an important cancer biomarker. This review will cover the extra-thyroidal distribution of NIS, as well as its pathophysiological implications in various tissues of human and non-human organs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.